首页BOT • ASX
add
Botanix Pharmaceuticals Ltd
市场资讯
财务信息
损益表
收入
净收入
| (AUD) | 2025年6月info | 年同比变化 |
|---|---|---|
收入 | 270.58万 | 219.92% |
经营支出 | 2689.60万 | 618.83% |
净收入 | -2775.40万 | -560.61% |
净利润率 | -1025.73 | -106.50% |
每股收益 | — | — |
息税折旧摊销前利润 | -2489.88万 | -492.72% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (AUD) | 2025年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 6496.66万 | -18.08% |
总资产 | 1.29亿 | 14.79% |
负债总额 | 4779.64万 | 1,180.69% |
权益总额 | 8129.89万 | — |
发行在外的股份 | 19.61亿 | — |
市净率 | 2.75 | — |
资产回报率 | -49.33% | — |
资本回报率 | -77.17% | — |
现金流
现金净变动
| (AUD) | 2025年6月info | 年同比变化 |
|---|---|---|
净收入 | -2775.40万 | -560.61% |
来自运营的现金 | -2401.16万 | -999.67% |
投资现金 | -9.80万 | 93.92% |
融资现金 | 3247.83万 | -4.95% |
现金净变动 | 826.49万 | -72.90% |
自由现金流 | -959.42万 | -245.54% |
简介
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
成立时间
1984
员工数量
11
